Studies on a new 1,5-benzothiazepine derivative (CRD-401). V. Antiarrhythmic actions.
D000319:Adrenergic beta-Antagonists; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy*; D001552:Benzazepines / Q000627:therapeutic use*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine; D006168:Guinea Pigs; D006329:Heart Conduction System / Q000187:drug effects; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D008297:Male; D010042:Ouabain; D011433:Propranolol / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001552:Benzazepines; D010042:Ouabain; D011433:Propranolol; D011802:Quinidine; D007545:Isoproterenol; D004837:Epinephrine